Ƶ

Eating Disorders After GLP-1s? Tirzepatide for Heart Failure; Soda Taxes and BMI

— News and commentary from the endocrinology world

Ƶ MedicalToday
Endo Break over a computer rendering of a man with illustrated body organs.

Weight-loss drugs like tirzepatide (Zepbound) and semaglutide (Wegovy) in certain patients, doctors warned. (NBC News)

In a placebo-controlled phase III trial, tirzepatide outcomes by 38% for adults with obesity and heart failure with preserved ejection fraction, Eli Lilly announced.

Bayer to the FDA for the treatment of moderate to severe menopause-related vasomotor symptoms with data from the phase III OASIS trials.

A case study in detailed how a 62-year-old man with obesity, hypothyroidism, and type 1 diabetes developed thyrotoxicosis due to excess exogenous levothyroxine intake after rapidly losing weight on tirzepatide.

All doses of for weight loss and diabetes (Mounjaro) are now available, according to the FDA's shortage list. (Reuters)

clarified that he has latent autoimmune diabetes in adults (LADA), sometimes called type 1.5 diabetes. (People)

lost 11.2% more of their body weight after 1 year on semaglutide 2.4 mg compared with placebo. They were also more likely to revert to normoglycemia, according to the latest study in the STEP clinical program. (Lancet Diabetes & Endocrinology)

City-level were associated with lower BMI in youths, a cohort study showed. (JAMA Network Open)

Compared with other antidiabetic medications, semaglutide (Ozempic) wasn't tied to a higher risk of over a 12-month period in a propensity score-matched cohort study. (eClinicalMedicine)

Postmenopausal women who had a had a lower prevalence of multimorbidity in a Chinese cross-sectional study. "This study highlights the growing body of evidence that links the duration of the reproductive lifespan in women with health outcomes such as cardiovascular disease and mortality," said Stephanie Faubion, MD, MBA, medical director of the North American Menopause Society. (Menopause)

Prescriptions for semaglutide have increased, with at retail pharmacies by December 2023; Ozempic accounted for most fills. (JAMA Health Forum)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.